Relevant bibliographies by topics / Hemolytic uremic syndrome Prevention

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Hemolytic uremic syndrome Prevention'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hemolytic uremic syndrome Prevention.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hemolytic uremic syndrome Prevention"

1

Yoshiya, Kunihiko, Kouichi Nakanishi, Seiko Itoh, Kazumoto Iijima, Norishige Yoshikawa, Hajime Nakamura, Tae Takeda, and Kazuhiro Kobayashi. "Etiology and prevention of hemolytic uremic syndrome." Nihon Shoni Jinzobyo Gakkai Zasshi 7, no. 2 (1994): 161–63. http://dx.doi.org/10.3165/jjpn.7.161.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Afshar-Kharghan, Vahid. "Atypical hemolytic uremic syndrome." Hematology 2016, no. 1 (December 2, 2016): 217–25. http://dx.doi.org/10.1182/asheducation-2016.1.217.

Full text
Abstract:
Abstract Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) that affects multiple organs and the kidneys in particular. aHUS can be sporadic or familial and is most commonly caused by dysregulation of the alternative complement pathway. The initial attack of aHUS can occur at any age, and is associated with a high rate of progression to end stage renal disease. Many aHUS patients relapse in the native or transplanted kidneys, and require close monitoring and long-term management. Availability of anticomplement therapy has revolutionized the management of aHUS, and
APA, Harvard, Vancouver, ISO, and other styles
3

Goldwater, Paul N. "Treatment and prevention of enterohemorrhagicEscherichia coliinfection and hemolytic uremic syndrome." Expert Review of Anti-infective Therapy 5, no. 4 (August 2007): 653–63. http://dx.doi.org/10.1586/14787210.5.4.653.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Haslam, David B. "Molecular Decoys: Novel Approaches to the Prevention of Hemolytic Uremic Syndrome." Pediatric Research 48, no. 3 (September 2000): 267–68. http://dx.doi.org/10.1203/00006450-200009000-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Joseph, Adrien, Aurélie Cointe, Patricia Mariani Kurkdjian, Cédric Rafat, and Alexandre Hertig. "Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review." Toxins 12, no. 2 (January 21, 2020): 67. http://dx.doi.org/10.3390/toxins12020067.

Full text
Abstract:
The severity of human infection by one of the many Shiga toxin-producing Escherichia coli (STEC) is determined by a number of factors: the bacterial genome, the capacity of human societies to prevent foodborne epidemics, the medical condition of infected patients (in particular their hydration status, often compromised by severe diarrhea), and by our capacity to devise new therapeutic approaches, most specifically to combat the bacterial virulence factors, as opposed to our current strategies that essentially aim to palliate organ deficiencies. The last major outbreak in 2011 in Germany, which
APA, Harvard, Vancouver, ISO, and other styles
6

TARR, PHILLIP I. "Escherichia coli O157: H7: Overview of Clinical and Epidemiological Issues." Journal of Food Protection 57, no. 7 (July 1, 1994): 632–37. http://dx.doi.org/10.4315/0362-028x-57.7.632.

Full text
Abstract:
Escherichia coli O157:H7 is an important and common human pathogen which causes diarrhea, bloody diarrhea (hemorrhagic colitis) and the life threatening post-diarrheal disorder, hemolytic uremic syndrome (HUS). Escherichia coli O157:H7 produces one or two potent cytotoxins, designated Shiga-like toxins (or verocytotoxins) I and II. While additional serotypes of cytotoxin-producing E. coli may cause human disease, E. coli O157:H7 is the most important such enteric pathogen in the United States. Epidemiologic data suggest that the incidence of hemolytic uremic syndrome is probably increasing. Un
APA, Harvard, Vancouver, ISO, and other styles
7

Davin, Jean-Claude, Charles Majoie, Jaap Groothoff, Valentina Gracchi, Antonia Bouts, Timothy H. J. Goodship, and Chantal Loirat. "Prevention of large-vessel stenoses in atypical hemolytic uremic syndrome associated with complement dysregulation." Pediatric Nephrology 26, no. 1 (July 24, 2010): 155–57. http://dx.doi.org/10.1007/s00467-010-1608-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nuernberger, Jens, Oliver Witzke, Russell P. Rother, Thomas Philipp, Udo Vester, Hideo Baba, Lothar Bernd Zimmerhackl, and Andreas Kribben. "Successful Treatment of Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab." Blood 112, no. 11 (November 16, 2008): 2294. http://dx.doi.org/10.1182/blood.v112.11.2294.2294.

Full text
Abstract:
Abstract Background: Atypical hemolytic uremic syndrome (aHUS) is a rare microangiopathic hemolytic anemia characterized by the uncontrolled progression of the alternative complement pathway due to genetic or acquired dysregulation of steady state alternative pathway activity leading to a proinflammatory and prothrombotic condition. Atypical HUS is characterized by intravascular hemolysis, consumptive thrombocytopenia, and microvascular glomerular thrombosis with the formation of thrombi in glomerular capillaries. As the thrombotic microangiopathy is particularly severe in the renal microvascu
APA, Harvard, Vancouver, ISO, and other styles
9

Noris, Marina, and Giuseppe Remuzzi. "Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation." Current Opinion in Nephrology and Hypertension 22, no. 6 (November 2013): 704–12. http://dx.doi.org/10.1097/mnh.0b013e328365b3fe.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Avila Bernabeu, Ana Isabel, Teresa Cavero Escribano, and Mercedes Cao Vilarino. "Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era." Nephron 144, no. 11 (2020): 537–49. http://dx.doi.org/10.1159/000508920.

Full text
Abstract:
Atypical hemolytic uremic syndrome (aHUS) is a rare cause of thrombotic microangiopathy (TMA), characterized by microangiopathic hemolytic anemia, consumptive thrombocytopenia, and multisystem end organ involvement, most commonly affecting the kidney. Diagnosis is clinical, after exclusion of other TMA causes. Primary aHUS arises from genetic abnormalities, resulting in uncontrolled complement activity, while a variety of clinical scenarios cause secondary aHUS, including infection, pregnancy, malignancy, autoimmune disease, and medications. They can also induce a temporary complement deregula
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Hemolytic uremic syndrome Prevention"

1

Srimanote, Potjanee. "Analysis of putative virulence factors of a locus of enterocyte effacement-negative shiga-toxigenic Escherichia coli O113:H21 strain." Title page, contents and abstract only, 2003. http://web4.library.adelaide.edu.au/theses/09PH/09php863.pdf.

Full text
Abstract:
"February 2003." Addendum and corrigenda inserted at back Includes bibliographical references (leaves 249-272) Aims to identify and characterise potential virulence-associated factors from the locus of enterocyte effacement-negative shiga-toxigenic Escherichia coli O113:H21 strain 98NK2 which was responsible for an outbreak of haemolytic uremic syndrome. Particular attention was focused on putative virulence genes encoded on the megaplasmid of this strain.
APA, Harvard, Vancouver, ISO, and other styles
2

Noris, Marina. "Genetics of hemolytic uremic syndrome." Maastricht : Maastricht : Universiteit Maastricht ; University Library, Maastricht University [Host], 2006. http://arno.unimaas.nl/show.cgi?fid=7591.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Maga, Tara Kristen. "Unraveling the complex genetics of atypical hemolytic uremic syndrome." Diss., University of Iowa, 2012. https://ir.uiowa.edu/etd/2935.

Full text
Abstract:
Atypical hemolytic uremic syndrome (aHUS) is characterized by acute renal failure, thrombocytopenia, and microangiopathic hemolytic anemia. aHUS is far less common and more severe than typical HUS, which is caused by E. coli infection and manifests as diarrheal illness. The pathogenesis of the disease is linked to dysregulation of the alternative pathway of the complement cascade. Mutations in the complement regulators factor H (CFH), membrane cofactor protein (MCP), factor B (CFB), and factor I (CFI) have been implicated
APA, Harvard, Vancouver, ISO, and other styles
4

Edwards, Kelly Katherine. "Bacterial factors contributing to the pathogenesis of the hemolytic uremic syndrome." MU has:, 2002. http://wwwlib.umi.com/cr/mo/fullcit?p3060096.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bu, Fengxiao. "Exploring the genetics of a complex disease - atypical hemolytic uremic syndrome." Diss., University of Iowa, 2016. https://ir.uiowa.edu/etd/3055.

Full text
Abstract:
Atypical hemolytic uremic syndrome (aHUS) is a rare renal disorder characterized by thrombotic microangiopathy, thrombocytopenia, and acute kidney injury. Its pathogenesis has been attributed to a ‘triggering' event that leads to dysregulation of the complement cascade at the level of the endothelial cell surface. Consistent with this understanding of the disease, mutations in complement genes have been definitively implicated in aHUS. However, the existence of other genetic contributors is supported by two observations. First, in ~50% of cases, disease-causing variants are not identified in c
APA, Harvard, Vancouver, ISO, and other styles
6

Karpman, Diana O. "Studies of the pathogenesis of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura." Lund : Lund University, 1997. http://catalog.hathitrust.org/api/volumes/oclc/68945090.html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Valoti, Elisabetta. "Genetic factors associated with anti-factor H autoantibodies in atypical hemolytic uremic syndrome (aHUS)." Thesis, Open University, 2018. http://oro.open.ac.uk/55853/.

Full text
Abstract:
Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy characterized by renal failure and determined by genetic and acquired defects of alternative pathway (AP) of the complement system. Autoantibodies against factor H (anti-FHs), a regulator of the AP, were reported in 10% of patients, and are associated with the deficiency of factor H related 1 (FHR1), a FH homologous protein. The aim of this thesis was to evaluate the contribution of genetics to the development of anti-FHs in aHUS. Thirty patients affected by aHUS resulted positive for anti-FHs (9.8%) and FHR
APA, Harvard, Vancouver, ISO, and other styles
8

Morigi, Marina. "Unravelling molecular and biochemical dysfunction by Shiga toxin: implication for thrombotic microangiopathy in Hemolytic Uremic Syndrome." Maastricht : Maastricht : Universiteit Maastricht ; University Library, Maastricht University [Host], 2006. http://arno.unimaas.nl/show.cgi?fid=7590.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Marinozzi, Maria Chiara. "Characterization of the complement hereditary and acquired abnormalities in atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy." Thesis, Sorbonne Paris Cité, 2016. http://www.theses.fr/2016USPCB037/document.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

McGannon, Colleen M. "Antibiotic Therapy in the Treatment of E. coli O157:H7." University of Cincinnati / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1230919332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Hemolytic uremic syndrome Prevention"

1

Parker, James N., and Philip M. Parker. The official patient's sourcebook on hemolytic uremic syndrome. Edited by Icon Group International Inc and NetLibrary Inc. San Diego, Calif: Icon Health Publications, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rotman, Tamara Avril. Role of verocytotoxin-1 in the pathogenesis of hemorrhagic colitis and hemolytic uremic syndrome. Ottawa: National Library of Canada, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

1941-, Kaplan Bernard S., Trompeter Richard S, and Moake Joel L. 1940-, eds. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. New York: Marcel Dekker, Inc., 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Clayton, Glenna. Hemolytic Uremic Syndrome: Symptoms, Treatment Options and Prognosis. Nova Science Publishers, Incorporated, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Globotriaosylceramide (Gb3) expression and membrane presentation: Implications for the hemolytic uremic syndrome and human immunodeficiency virus infection. Ottawa: National Library of Canada, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Publications, ICON Health. The Official Patient's Sourcebook on Hemolytic Uremic Syndrome: A Revised and Updated Directory for the Internet Age. Icon Health Publications, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Enterohemorrhagic Escherichia coli and Other Shiga Toxin-Producing E. coli. ASM Press, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

F, Zipfel Peter, ed. Complement and kidney disease. Basel: Birkhäuser, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Escherichia coli O157:H7 and other shiga toxin-producing E. coli strains. Washington, DC: ASM Press, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Hemolytic uremic syndrome Prevention"

1

Sethi, Sidharth Kumar. "Hemolytic Uremic Syndrome." In Critical Care Pediatric Nephrology and Dialysis: A Practical Handbook, 187–94. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-2276-1_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ali, Uma, and Bradley P. Dixon. "Hemolytic Uremic Syndrome." In Critical Care Nephrology and Renal Replacement Therapy in Children, 129–44. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-90281-4_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Metze, Dieter, Vanessa F. Cury, Ricardo S. Gomez, Luiz Marco, Dror Robinson, Eitan Melamed, Alexander K. C. Leung, et al. "Hemolytic Uremic Syndrome." In Encyclopedia of Molecular Mechanisms of Disease, 801–2. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-29676-8_763.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Clark, Elaine, and Scott Orme. "Hemolytic-uremic syndrome." In Health-related disorders in children and adolescents: A guidebook for understanding and educating., 309–14. Washington: American Psychological Association, 1998. http://dx.doi.org/10.1037/10300-042.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Eddins, Michelle McCown. "Hemolytic-Uremic Syndrome." In Consults in Obstetric Anesthesiology, 255–56. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-59680-8_73.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sethna, Christine B., and Shari Gurusinghe. "Hemolytic Uremic Syndrome." In Glomerulonephritis, 1–19. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-27334-1_42-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Vercellone, Antonio, Piero Stratta, and Caterine Canavese. "Hemolytic Uremic Syndrome." In Advances in Experimental Medicine and Biology, 185–98. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-8240-9_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sethna, Christine B., and Shari Gurusinghe. "Hemolytic Uremic Syndrome." In Glomerulonephritis, 647–65. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-49379-4_42.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Johnson, S., and C. Mark Taylor. "Hemolytic Uremic Syndrome." In Pediatric Nephrology, 1155–80. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-76341-3_48.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Watkins, Sandra L. "Hemolytic Uremic Syndrome." In Textbook of Clinical Pediatrics, 2769–72. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-02202-9_297.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Hemolytic uremic syndrome Prevention"

1

Bahlavouni, Alina, and Aleena Paul. "Hemolytic Uremic Syndrome Associated with Entamoeba Histolytica." In AAP National Conference & Exhibition Meeting Abstracts. American Academy of Pediatrics, 2021. http://dx.doi.org/10.1542/peds.147.3_meetingabstract.866.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Selvam, M. Masilamani, Divya Sasitharan, and W. Manohar Paul. "Clinical validation of vaccines against hemolytic uremic syndrome." In 2014 International Conference on Science Engineering and Management Research (ICSEMR). IEEE, 2014. http://dx.doi.org/10.1109/icsemr.2014.7043626.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pankratenko, T. E., O. V. Moskalec, and T. Yu Abaseeva T. "Cell adhesion molecules in childrenwith diarrhea-associated hemolytic uremic syndrome." In General question of world science. "Л-Журнал", 2018. http://dx.doi.org/10.18411/gq-31-03-2018-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Moskalec, O. V., T. E. Pankratenko, and T. Yu Abaseeva. "Soluble adhesion molecules in children with typical hemolytic uremic syndrome." In Scientific achievements of the third millennium. SPC "LJournal", 2018. http://dx.doi.org/10.18411/scc-05-2018-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Abdou, M., M. Alsharif, T. Naguib, and M. L. Patel. "Eculizumab: A Life Saver in Postpartum Atypical Hemolytic Uremic Syndrome." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6530.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

ROMERO LEGRO, IVAN, Sadia Shah, and Vaidehi Kaza. "Tacrolimus Induced Hemolytic Uremic Syndrome In A Lung Transplant Patient." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5834.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Moskalets, O. V., T. E. Pankratenko, and T. Yu Abaseeva. "Biomarkers of endothelial disfunction in children with atypical hemolytic uremic syndrome." In Scientific achievements of the third millennium. SPC "LJournal", 2018. http://dx.doi.org/10.18411/scc-09-2018-08.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cruz, Pedro Costa e., Patrícia Mendes, Marisol Anselmo, and Luís Gonçalves. "P102 Typical vs atypical hemolytic-uremic syndrome: eculizumab, a difficult decision." In 8th Europaediatrics Congress jointly held with, The 13th National Congress of Romanian Pediatrics Society, 7–10 June 2017, Palace of Parliament, Romania, Paediatrics building bridges across Europe. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2017. http://dx.doi.org/10.1136/archdischild-2017-313273.190.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Moskalets, O. V. "Prognostic value of sICAM-1 and sVCAM-1 in hemolytic uremic syndrome." In Global science. Development and novelty. НИЦ «Л-Журнал», 2018. http://dx.doi.org/10.18411/gdsn-25-12-2018-04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pankratenko, T. E., and O. V. Moskalec. "sICAM-1 and sVCAM-1 in children with typical hemolytic uremic syndrome." In Global science. Development and novelty. НИЦ «Л-Журнал», 2018. http://dx.doi.org/10.18411/gdsn-28-02-2018-07.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Hemolytic uremic syndrome Prevention' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography